TVTX Reports $124.5M Revenue, $4.1M Adjusted Net Income, FDA Approves FILSPARI for FSGS, Launches Phase 3 HARMONY Study
Travere Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $47.18
-5.0% in 3d after detection
Post-detection moves
1h
—
1d
-0.2%
3d
-5.0%
7d
-0.8%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS